Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Scientific, Inc. filings document its high-density colocation data center business, digital asset mining activities, capital structure and public-company governance. Recent 8-K reports cover operating and financial results, Regulation FD disclosures, campus expansion updates, material agreements, debt financing and direct financial obligations.
The company’s filings also describe common stock and warrant securities listed on the Nasdaq Global Select Market, subsidiary financing arrangements, senior secured notes, credit agreement amendments, executive and accounting-officer governance matters, and annual proxy disclosures for shareholder voting, board matters and compensation programs.
Core Scientific, Inc. Chief Executive Officer Adam Taylor Sullivan reported a routine tax-related share disposition. A total of 18,023 shares of common stock were withheld on June 30, 2026 to cover withholding tax obligations triggered by the vesting of restricted stock units. This was not an open-market sale, but an automatic tax-withholding event. Following the transaction, Sullivan directly owned 4,452,010 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on June 29, 2026 at weighted average prices of about $25.99, $27.42 and $27.95, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
On June 30, 2026, an additional 5,469 shares were disposed of to satisfy withholding tax obligations upon vesting of restricted stock units, a non-market transaction. After these actions, Duchene directly owned 2,033,426 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling a total of 10,000 shares of Common Stock in open-market transactions. The sales occurred on June 22, 2026 at weighted average prices of $29.11 and $29.88, based on multiple trades within stated price ranges.
The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were scheduled in advance. After the transactions, he continues to hold a substantial direct equity position in Core Scientific.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of common stock in open-market transactions. The sales occurred on June 15, 2026 in two trades at weighted average prices of $28.79 and $28.19 per share. According to the disclosure, these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the timing was scheduled in advance rather than a discretionary move.
Core Scientific, Inc. reported that officer Todd M. Duchene sold a total of 10,000 shares of common stock in the open market on June 8, 2026. The sales occurred in two blocks: 4,500 shares at a weighted average price of $27.1053 per share and 5,500 shares at a weighted average price of $26.6376 per share.
The filing notes that these transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025, meaning the trades were pre-arranged rather than timed at the officer’s discretion.
Core Scientific, Inc. officer Todd M. Duchene reported selling a total of 10,000 shares of Common Stock on June 1, 2026 in open-market transactions. The sales were executed in three blocks at weighted average prices of $26.9285, $28.2666, and $28.7561 per share.
The filing notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Footnotes explain that each reported price is a weighted average for multiple individual trades within price ranges from $26.54 to $28.97.
Smith Stephen M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific director Stephen M. Smith received a grant of 18,961 shares of Common Stock in the form of restricted stock units. The RSUs were granted at no cash cost and will vest in two substantially equal installments on May 26, 2027 and May 26, 2028, contingent on his continued service.
Core Scientific, Inc. director Stephen M. Smith filed an initial ownership report on Form 3. This filing identifies him as a director of the company but does not list any specific share or option holdings or transactions at this time.
Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on May 26, 2026 at a weighted average price of $26.254 per share. The transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were pre-scheduled. After these sales, Duchene directly holds 2,088,895 shares, so the sale represents a relatively small portion of his overall position. The shares were sold in multiple trades at prices ranging from $25.81 to $26.75.
Jane Street Group, LLC reports beneficial ownership of 23,967,780 shares of Core Scientific, Inc./tx common stock, representing 7.5% of the class. The filing identifies subsidiary holdings: Jane Street Capital, LLC (20,703,298 shares; 6.5%) and Jane Street Global Trading, LLC (3,264,482 shares; 1.0%). The statement shows shared voting and shared dispositive power over the 23,967,780 shares and is signed by Jeremy Kahn as authorized signatory.